Suppr超能文献

假说:金属元素对肺动脉高压发病机制的潜在贡献。

A hypothesis: Potential contributions of metals to the pathogenesis of pulmonary artery hypertension.

机构信息

Department of Anesthesiology and Perioperative Medicine, University of Louisville School of Medicine, Louisville, KY, USA.

Department of Internal Medicine, Division of Pulmonary Critical Care and Sleep Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.

出版信息

Life Sci. 2024 Jan 1;336:122289. doi: 10.1016/j.lfs.2023.122289. Epub 2023 Nov 24.

Abstract

Pulmonary artery hypertension (PAH) is characterized by vasoconstriction and vascular remodeling resulting in both increased pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP). The chronic and high-pressure stress experienced by endothelial cells can give rise to inflammation, oxidative stress, and infiltration by immune cells. However, there is no clearly defined mechanism for PAH and available treatment options only provide limited symptomatic relief. Due to the far-reaching effects of metal exposures, the interaction between metals and the pulmonary vasculature is of particular interest. This review will briefly introduce the pathophysiology of PAH and then focus on the potential roles of metals, including essential and non-essential metals in the pathogenic process in the pulmonary arteries and right heart, which may be linked to PAH. Based on available data from human studies of occupational or environmental metal exposure, including lead, antimony, iron, and copper, the hypothesis of metals contributing to the pathogenesis of PAH is proposed as potential risk factors and underlying mechanisms for PAH. We propose that metals may initiate or exacerbate the pathogenesis of PAH, by providing potential mechanism by which metals interact with hypoxia-inducible factor and tumor suppressor p53 to modulate their downstream cellular proliferation pathways. These need further investigation. Additionally, we present future research directions on roles of metals in PAH.

摘要

肺动脉高压(PAH)的特征是血管收缩和血管重塑,导致肺血管阻力(PVR)和肺动脉压力(PAP)均升高。内皮细胞长期承受高压应激,会引发炎症、氧化应激和免疫细胞浸润。然而,PAH 的发病机制尚未明确,现有的治疗方法仅能提供有限的症状缓解。由于金属暴露的影响深远,金属与肺血管的相互作用尤其受到关注。本综述将简要介绍 PAH 的病理生理学,然后重点关注金属(包括必需和非必需金属)在肺动脉和右心发病过程中的潜在作用,这些作用可能与 PAH 有关。基于职业或环境金属暴露的人体研究中获得的数据,包括铅、锑、铁和铜,提出了金属可能导致 PAH 发病的假说,认为金属是 PAH 的潜在危险因素和潜在发病机制。我们提出,金属可能通过提供金属与缺氧诱导因子和肿瘤抑制因子 p53 相互作用的潜在机制,来启动或加重 PAH 的发病,从而调节其下游细胞增殖途径。这需要进一步研究。此外,我们还提出了金属在 PAH 中的作用的未来研究方向。

相似文献

1
A hypothesis: Potential contributions of metals to the pathogenesis of pulmonary artery hypertension.
Life Sci. 2024 Jan 1;336:122289. doi: 10.1016/j.lfs.2023.122289. Epub 2023 Nov 24.
2
Caspase-4/11-Mediated Pulmonary Artery Endothelial Cell Pyroptosis Contributes to Pulmonary Arterial Hypertension.
Hypertension. 2022 Mar;79(3):536-548. doi: 10.1161/HYPERTENSIONAHA.121.17868. Epub 2022 Jan 5.
3
Potential Roles of Metals in the Pathogenesis of Pulmonary and Systemic Hypertension.
Int J Biol Sci. 2023 Sep 25;19(16):5036-5054. doi: 10.7150/ijbs.85590. eCollection 2023.
5
Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
Am J Respir Crit Care Med. 2019 Oct 1;200(7):910-920. doi: 10.1164/rccm.201812-2275OC.
6
High Shear Stress Reduces ERG Causing Endothelial-Mesenchymal Transition and Pulmonary Arterial Hypertension.
Arterioscler Thromb Vasc Biol. 2025 Feb;45(2):218-237. doi: 10.1161/ATVBAHA.124.321092. Epub 2024 Dec 26.
7
Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension.
Circulation. 2023 May 23;147(21):1606-1621. doi: 10.1161/CIRCULATIONAHA.122.061940. Epub 2023 Apr 17.
10
Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension.
Molecules. 2022 Jun 9;27(12):3724. doi: 10.3390/molecules27123724.

本文引用的文献

1
p53 contributes to cardiovascular diseases via mitochondria dysfunction: A new paradigm.
Free Radic Biol Med. 2023 Nov 1;208:846-858. doi: 10.1016/j.freeradbiomed.2023.09.036. Epub 2023 Sep 29.
2
Ferrostatin-1 Blunts Right Ventricular Hypertrophy and Dysfunction in Pulmonary Arterial Hypertension by Suppressing the HMOX1/GSH Signaling.
J Cardiovasc Transl Res. 2024 Feb;17(1):183-196. doi: 10.1007/s12265-023-10423-4. Epub 2023 Aug 21.
5
Type 1 Pulmonary Hypertension and Silicosis in a Bluestone Cutter: A Case Report on Raising Awareness.
Cureus. 2023 Feb 24;15(2):e35425. doi: 10.7759/cureus.35425. eCollection 2023 Feb.
7
The role of hypoxia-inducible factor 1 alpha (HIF-1α) modulation in heavy metal toxicity.
Arch Toxicol. 2023 May;97(5):1299-1318. doi: 10.1007/s00204-023-03483-7. Epub 2023 Mar 18.
8
Metallomics in pulmonary arterial hypertension patients.
Pulm Circ. 2023 Feb 21;13(1):e12202. doi: 10.1002/pul2.12202. eCollection 2023 Jan.
10
Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia.
JACC Asia. 2022 Aug 2;2(5):538-546. doi: 10.1016/j.jacasi.2022.04.008. eCollection 2022 Oct.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验